The Call Bristol-Myers Squibb Bulls Got Right

If you had been weighing Bristol-Myers Squibb against its looming patent cliffs and the promise of late-stage oncology drugs back in October 2025, the result now looks very different on paper. Holding Bristol-Myers Squibb over the past year would have returned 46.5%, including dividends. The question is simple: faced with aging demographics, genomics-driven treatments and debt concerns, what did early buyers think would matter most for this business? Narratives are how investors here put a...